دورية أكاديمية
Teprotumumab for chronic thyroid eye disease.
| العنوان: | Teprotumumab for chronic thyroid eye disease. |
|---|---|
| المؤلفون: | Ozzello DJ; Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, La Jolla, California, USA., Dallalzadeh LO; Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, La Jolla, California, USA., Liu CY; Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, La Jolla, California, USA. |
| المصدر: | Orbit (Amsterdam, Netherlands) [Orbit] 2022 Oct; Vol. 41 (5), pp. 539-546. Date of Electronic Publication: 2021 Jun 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8301221 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5108 (Electronic) Linking ISSN: 01676830 NLM ISO Abbreviation: Orbit Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: Amsterdam : Aeolus Press, [1982- |
| مواضيع طبية MeSH: | Exophthalmos* , Eyelid Diseases* , Graves Ophthalmopathy*/diagnosis, Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies |
| مستخلص: | Purpose: To describe the treatment of nine patients with chronic, low clinical activity score thyroid eye disease with teprotumumab. Methods: A retrospective series of patients with chronic thyroid eye disease (TED) and low clinical activity score (CAS) treated with teprotumumab infusion therapy. Inclusion criteria: adults over 18 years of age with TED for greater than 9 months and CAS of 1 or less. All patients included in the analyses completed a full series of eight infusions. Primary outcome measures included proptosis and eyelid retraction in both eyes. Secondary outcomes included CAS, reported adverse effects, and surgery post-treatment. Results: Nine patients met all inclusion criteria, seven females and two males with mean age of 50.2 years and TED diagnosis of 6.25 years. Three patients had a baseline CAS of 1 and 6 had a CAS of 0. Mean proptosis reduction in the worse eye was 4.0 ± 2.4 mm immediately post-treatment ( p = .02). Five out of nine patients had extended follow-up (average 16.8 ± 5.1 weeks) with mean proptosis reduction of 4.2 ± 2.8 mm at last follow-up ( p = .03). Mean reduction in eyelid retraction in the worse eye was 0.3 ± 1.6 mm post-treatment ( p = .58) and 0.5 ± 0.9 mm at last follow-up ( p = .30). Three patients reported infusion-related myalgias, two hair thinning, one exacerbated chronic tinnitus, and one hyperglycemia. Conclusions: We report clinically and statistically significant proptosis reduction in nine patients with chronic, low CAS TED treated with teprotumumab. Teprotumumab may be an effective treatment option for these patients. |
| فهرسة مساهمة: | Keywords: Chronic; proptosis; teprotumumab; thyroid eye disease |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) Y64GQ0KC0A (teprotumumab) |
| تواريخ الأحداث: | Date Created: 20210601 Date Completed: 20220823 Latest Revision: 20220823 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1080/01676830.2021.1933081 |
| PMID: | 34060414 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-5108 |
|---|---|
| DOI: | 10.1080/01676830.2021.1933081 |